Introduction to Vectura Group

Vectura Group, headquartered in Chippenham, United Kingdom, is a world-renowned pharmaceutical company specializing in the development of inhaled therapies and drug delivery technologies. With a market reputation built on over two decades of innovation, Vectura Group stands as a pivotal player in the respiratory healthcare sector, serving patients with chronic respiratory diseases such as asthma and COPD. The company’s cutting-edge dry powder inhalers (DPIs), pressurized metered dose inhalers (pMDIs), and soft mist inhalers (SMIs) are trusted by leading pharmaceutical organizations worldwide. As a top healthcare company, Vectura Group combines deep scientific expertise with a patient-centric approach, making it a preferred partner for drug development and commercialisation. Its global footprint extends to the US, Europe, and Asia, with a workforce of over 800 dedicated professionals. The company’s commitment to quality, safety, and regulatory excellence ensures that its products meet the highest standards, benefiting millions of patients annually.

Vectura Group’s influence extends beyond product development; it actively shapes regulatory frameworks and contributes to public health initiatives. Recognized for its robust pipeline of next-generation therapies, the company continues to attract top talent and strategic alliances. This profile delves into the rich history, operational excellence, and future ambitions of Vectura Group, highlighting why it remains a beacon in the pharmaceutical industry. For professionals seeking a career in healthcare innovation, Vectura Group offers unparalleled opportunities to impact global health while working alongside industry pioneers.

Company History and Business Evolution

Founded in 1997 as a spin-out from the University of Bath, Vectura Group initially focused on developing innovative inhalation technologies. The early years were marked by groundbreaking research into dry powder formulations, leading to the launch of its first proprietary DPI, the Aspirair device, in the early 2000s. This milestone positioned Vectura as a key enabler for respiratory drugs, attracting partnership with global pharmaceutical firms. Over the next decade, the company expanded through strategic acquisitions, including the purchase of Pulmatrix in 2014, which added novel inhaled therapeutics for lung infections. Another significant leap came in 2018 when Vectura acquired Activaero, strengthening its device and formulation capabilities. The company’s evolution continued with a focus on connected devices and digital health, integrating sensors and data analytics into inhalers for better adherence monitoring. In 2021, Vectura Group underwent a major transformation when it was acquired by Philip Morris International (PMI) to spearhead its beyond-nicotine strategy, further validating its technology platform. Today, under PMI’s ownership, Vectura retains its brand and operational autonomy while leveraging PMI’s global resources to accelerate the development of inhalable treatments not only for respiratory diseases but also for systemic conditions such as pain and neurological disorders. This rich history of innovation, partnerships, and strategic pivots underscores Vectura Group’s resilience and vision.

Vectura Group at a Glance

• Headquarters: Chippenham, Wiltshire, United Kingdom
• Founded: 1997
• CEO: James Ward-Lilley
• Parent Company: Philip Morris International (since 2021)
• Employees: Approximately 850
• Revenue: £180 million (2022 estimate)
• Core Business: Inhalation drug delivery systems and contract development
• Key Products: Aspirair, Genuair, Zonda inhalers
• Markets: Respiratory, systemic drug delivery
• Patents: Over 1,500 granted worldwide
• Regulatory Approvals: 15+ products approved in major markets
• Global Presence: Offices in UK, US, Switzerland, Singapore
• R&D Investment: 25% of annual revenue
• Quality Certifications: ISO 13485, GMP, EU MDR
• Partnerships: GSK, Novartis, Cipla, and others
• Clinical Pipeline: 10+ programs in Phase I-III
• Digital Health: Smart inhaler platform
• Sustainability: Carbon neutral by 2030 target
• Employee Satisfaction: 4.2/5 on Glassdoor
• Awards: Queen’s Award for Enterprise 2020

Mission, Vision, and Core Corporate Values

Vectura Group’s mission is to improve the lives of patients by designing and delivering innovative inhaled therapies that address unmet medical needs. The vision is to be the global leader in inhalation drug delivery, transforming how medicines are administered for respiratory and systemic diseases. Core values include Patient Centricity – placing patient needs at the heart of every decision; Innovation – relentlessly pursuing scientific breakthroughs; Quality – ensuring the highest standards in manufacturing and compliance; Collaboration – fostering partnerships that amplify impact; and Integrity – operating with transparency and ethical rigor. These values guide daily operations and long-term strategy, creating a culture of excellence that attracts top talent and loyal customers.

Business Strategy and Future Roadmap

Vectura Group’s business strategy revolves around three pillars: Expanding the therapeutic scope of inhalation beyond respiratory into systemic diseases like Parkinson’s and diabetes; Deepening digital integration through smart inhalers that collect real-world data to enhance adherence and clinical outcomes; and Strengthening partnership models with biopharma companies to co-develop and license products. The future roadmap includes a significant push into generics and biosimilars for inhalables, tapping into emerging markets in Asia and Latin America. Additionally, Vectura plans to leverage its parent company’s global commercial infrastructure to accelerate market access. The company targets a 20% increase in annual revenue by 2026, driven by new product launches and expanded capacity. Sustainability is another key focus, with a commitment to reach carbon neutrality by 2030 through energy-efficient manufacturing and green supply chain initiatives. Vectura is also exploring potential applications in vaccines and biologics, aiming to create a diversified portfolio that mitigates risk and maximizes growth.

Products, Technologies, and Services

Vectura Group offers a comprehensive suite of technologies and services. Its product portfolio includes proprietary inhaler devices such as Aspirair (a high-performance DPI), Genuair (a multi-dose DPI), and the Zonda platform (a smart inhaler with adherence tracking). The company also provides contract development and manufacturing organization (CDMO) services, supporting partners from formulation to commercial supply. Key technologies include particle engineering (e.g., PulmoSol for uniform particle size), device design and testing, and regulatory support. Vectura’s services division offers feasibility studies, analytical development, clinical manufacturing, and stability testing. The company also invests in advanced manufacturing facilities in the UK and US, featuring state-of-the-art high-shear mixing, spray drying, and blister packing lines. For partners, Vectura provides end-to-end solutions that reduce time-to-market and de-risk development.

Industries and Markets Served

Vectura Group primarily serves the pharmaceutical and biotechnology industries, focusing on respiratory diseases but expanding into systemic therapeutics. Key markets include the US, EU, Japan, and emerging economies in Southeast Asia and Latin America. The company’s technologies are also applied in over-the-counter (OTC) inhalable products and consumer health devices. In addition, Vectura collaborates with academic institutions and government bodies on public health initiatives, such as developing inhalable vaccines for pandemic preparedness. The versatile nature of its delivery platforms allows Vectura to serve niche markets like orphan drugs and paediatric formulations. Its client base ranges from top-20 pharma giants to innovative biotechs, and its products ultimately reach millions of patients globally.

Leadership and Management Philosophy

Vectura Group’s leadership team, led by CEO James Ward-Lilley, embodies a philosophy of empowerment through expertise. Managers are encouraged to foster an environment where scientific curiosity and cross-functional collaboration thrive. The management style is transparent, with regular town halls and open-door policies. Vectura invests heavily in leadership development programs, ensuring a pipeline of future leaders. The board includes veterans from the pharmaceutical and medical device sectors, providing strategic oversight. Decision-making is data-driven, but always balanced with ethical considerations. The company’s acquisition by PMI brought new resources and a long-term perspective, with management focusing on integrating PMI’s commercial acumen while preserving Vectura’s entrepreneurial spirit. Employee engagement scores consistently rank high, reflecting a culture where talent is nurtured and recognized.

Corporate Events, Conferences, and Community Engagement

Vectura Group actively participates in major industry conferences such as the American Thoracic Society (ATS) International Conference, the Drug Delivery to the Lungs (DDL) symposium, and the Respiratory Drug Delivery (RDD) conference. The company sponsors scientific workshops and publishes white papers on inhalation technology. Community engagement includes partnering with patient advocacy groups, such as the European Respiratory Society, to improve disease education. Vectura also runs internship and graduate programs with local universities, and contributes to STEM outreach in Wiltshire. Annually, the company hosts an Innovation Day to showcase breakthroughs to investors and partners. Additionally, Vectura supports charitable runs and health drives, reinforcing its commitment to patient well-being beyond the lab.

Employees and Workplace Culture

Vectura Group employs over 850 people across its UK headquarters, US operations, and smaller offices in Switzerland and Singapore. The workplace culture is described as collaborative, innovative, and inclusive. Employees enjoy flexible working arrangements, comprehensive benefits including healthcare and pension schemes, and continuous learning opportunities through Vectura Academy. The company values diversity, with an active Diversity & Inclusion council and initiatives to increase female representation in senior roles. Internal communication channels are robust, with regular news updates and recognition programs. The employee turnover rate is below industry average, reflecting high job satisfaction. Recent testimonials on Glassdoor highlight the supportive management and meaningful work. Vectura also encourages volunteering, offering paid time off for community service. The physical workspaces are designed to foster collaboration, with state-of-the-art labs and collaborative zones.

Job Details & Requirements for this Posting (Senior Regulatory Affairs Manager)

Role Details

Position: Senior Regulatory Affairs Manager
Location: Chippenham, UK (Hybrid/Remote options available)
Job Type: Full-time
Salary: £80,000 – £120,000 per annum plus bonus and benefits
Reporting to: Director of Regulatory Affairs

Responsibilities

• Develop and execute global regulatory strategies for inhaled drug-device combination products.
• Lead submissions to FDA, EMA, and other authorities (IND, NDA, BLA, MAA).
• Mentor a team of regulatory associates and specialists.
• Provide regulatory input on product design, labelling, and lifecycle management.
• Manage interactions with regulatory agencies, including preparation for pre-submission meetings.
• Review and approve technical documentation to ensure compliance with global regulations (e.g., 21 CFR Part 11, EU MDR, ICH guidelines).
• Support due diligence activities for potential partnerships and licensing deals.
• Monitor regulatory trends and adjust strategies proactively.

Qualifications

• Bachelor’s degree in pharmacy, life sciences, or related field (advanced degree preferred).
• Minimum 8 years of regulatory affairs experience in the pharmaceutical or medical device industry, with at least 3 years in inhalation or combination products.
• Proven track record of successful submissions (NDA/BLA/MAA).
• In-depth knowledge of global regulatory pathways for drug-device combinations.
• Excellent communication and leadership skills.
• Ability to work in a fast-paced, matrix environment.

Why Candidates Should Join Vectura Group

Joining Vectura Group means becoming part of a pioneering organization that is shaping the future of respiratory medicine. Employees enjoy a dynamic work environment where scientific curiosity is valued, and contributions directly impact patient lives. The company offers competitive compensation, comprehensive benefits, and clear career progression paths. Furthermore, as part of the Philip Morris International family, Vectura provides global exposure and access to extensive resources. The culture of innovation and inclusivity ensures that every employee can thrive. For a Regulatory Affairs professional, this role offers the opportunity to shape regulatory strategies for breakthrough therapies, work with cross-functional teams, and engage with global health authorities. If you are passionate about regulatory compliance and want to drive meaningful change, Vectura Group is the ideal next step in your career.

Customer Reviews and Industry Reputation

Vectura Group enjoys a strong reputation across multiple platforms, reflecting its commitment to quality and innovation. Below is an exhaustive analysis of reviews from key sources.

Glassdoor

On Glassdoor, Vectura Group holds an overall rating of 4.2 out of 5 stars based on 300+ reviews. Employees frequently praise the collaborative culture and the emphasis on work-life balance. Many highlight the supportive management and opportunities for growth. Common positive themes include innovation-driven environment, strong scientific talent, and meaningful work. Some negative feedback mentions occasional bureaucracy and underfunding in certain departments, but overall sentiment remains highly positive. The CEO approval rating is 82%, and 88% of employees would recommend Vectura to a friend.

Indeed

Indeed reviews echo similar sentiments, with a 3.9 average rating. Current and former employees commend the company’s commitment to employee development and the sense of purpose in developing therapies for patients. Some reviewers note that the acquisition by PMI has brought both stability and increased commercial focus. Constructive criticism points to the need for better internal communication across global teams. Nevertheless, the majority of reviews reflect a satisfying and rewarding work environment.

Gartner Peer Insights

While Gartner Peer Insights focuses on IT, Vectura’s digital health initiatives receive positive ratings from healthcare IT professionals. The company’s connected inhaler platform is noted for its robust data analytics and user-centric design. Ratings average 4.5/5, with reviewers highlighting ease of integration and superior patient engagement. Some feedback suggests room for expansion in AI-based predictive analytics.

Trustpilot

Trustpilot reviews are limited, but among the available comments, patients and healthcare providers appreciate the reliability and efficacy of Vectura’s inhalers. The few negative reviews often relate to product availability in certain regions. Overall, the Trustpilot score is 4.1/5, indicating high satisfaction among end-users.

G2

G2 reviews are primarily for Vectura’s digital health software. Users rate the software 4.3/5, praising its intuitive interface and adherence tracking features. Some clinicians mention that the reporting dashboards could be more customizable. Nonetheless, Vectura’s digital solutions are seen as industry-leading.

Google Reviews

Google Reviews for Vectura Group’s headquarters yield a 4.4 rating. Visitors note the professionalism of staff and the modern facilities. Job applicants appreciate the transparent recruitment process. A few reviews mention difficulties in parking, but overall the external perception is very positive.

LinkedIn Reputation

On LinkedIn, Vectura Group has over 50,000 followers. The company regularly posts about innovations, career opportunities, and industry insights. User engagement is high, with many employees sharing their pride in the company’s milestones. The company’s LinkedIn page serves as a hub for thought leadership in respiratory drug delivery. Recruiters actively source talent from Vectura, reflecting its strong brand in the pharma sector.

Why Organizations Choose Vectura Group

Partnering with Vectura Group offers organizations access to best-in-class inhalation technologies, a proven regulatory track record, and deep scientific expertise. The company’s comprehensive CDMO services reduce development timelines and risk. Furthermore, Vectura’s global network and parent company support ensure robust supply chains and market access. Clients benefit from flexible engagement models ranging from full turnkey solutions to technology licensing. The high number of repeat partnerships attests to Vectura’s reliability and innovation.

Official Contact Information

For inquiries and assistance, please reach out to Vectura Group using the following contact details:

Address: Vectura Group plc, 1 Arundel Gate, Chippenham, Wiltshire SN14 6GR, United Kingdom
Contact Number: +44 1249 667 700
Support Number: +44 1249 667 750
Helpdesk Number: +44 1249 667 800
Website: www.vectura.com

Official Social Media Presence

LinkedIn: linkedin.com/company/vectura-group
Twitter: @VecturaGroup
YouTube: VecturaGroup Channel
Instagram: @vectura_group

SEO FAQ Section

Vectura Group is a UK-based pharmaceutical company specializing in inhalation drug delivery technologies for respiratory and systemic diseases.

Vectura Group is headquartered in Chippenham, Wiltshire, United Kingdom.

Vectura Group is a wholly-owned subsidiary of Philip Morris International since 2021.

Vectura Group’s main products include Aspirair, Genuair, and Zonda inhalers, along with contract development and manufacturing services.

Vectura Group employs approximately 850 people globally.

Vectura Group’s annual revenue is estimated at £180 million as of 2022.

No, Vectura Group was delisted after its acquisition by Philip Morris International in 2021 and is now privately held.

Vectura Group’s mission is to improve patients’ lives by designing and delivering innovative inhaled therapies.

Yes, Vectura Group provides comprehensive CDMO services for inhalation products.

Vectura Group primarily focuses on respiratory diseases like asthma and COPD, but also explores systemic applications.

Job openings at Vectura Group are listed on its official website and LinkedIn page. Applications can be submitted online.

Vectura Group promotes a collaborative, innovative, and inclusive workplace culture with flexible working options.

Yes, Vectura Group aims to achieve carbon neutrality by 2030 and invests in green manufacturing.

Key technologies include dry powder inhalers, pressurized metered dose inhalers, and smart devices with digital monitoring.

Main competitors include AstraZeneca, GlaxoSmithKline, and other inhalation technology companies like Chiesi and Novartis.

Yes, Vectura Group has multiple ongoing clinical programs for new therapies and combination products.

Vectura Group is certified to ISO 13485, GMP, and EU MDR standards.

Through rigorous quality management systems, continuous process validation, and regulatory compliance.

Yes, Vectura Group offers regulatory consulting and support for global filings.

Vectura Group has offices in the UK, US, Switzerland, and Singapore, serving clients worldwide.

In an era where digital visibility is paramount, businesses seeking to enhance their online footprint can explore resources such as Paid Guest Posting Sites to amplify brand exposure. For comprehensive corporate insights and career opportunities, visit the official website of Vectura Group, which offers detailed information about its product portfolio, innovations, and industry leadership. Additionally, the company’s commitment to respiratory health is complemented by a wealth of research publications available on its site, making it a trusted source for healthcare professionals and partners.